Sosman, Jeffrey A.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 367

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 338

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 287

Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609

Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 184

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J.-E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., et al. (2019) · Nature Medicine

Cancer Immunotherapy and BiomarkersAutoimmune Neurological Disorders and Treatments

Cited by 176

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.

Sosman, J. A., Kittaneh, M., Lolkema, M. P. J. K., Postow, M. A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., & Kim, K. (2014) · Journal of Clinical Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 129

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Costa, R., Carneiro, B. A., Agulnik, M., Rademaker, A. W., Pai, S. G., Villaflor, V. M., Cristofanilli, M., Sosman, J. A., & Giles, F. J. (2017) · Oncotarget

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 123

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells

Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research

Cancer-related Molecular PathwaysTelomeres, Telomerase, and Senescence

Cited by 115

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

Johnson, D. B., Friedman, D. L., Berry, E., Decker, I., Ye, F., Zhao, S., Morgans, A. K., Puzanov, I., Sosman, J. A., & Lovly, C. M. (2015) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 101

Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment

Vilgelm, A. E., Johnson, C. A., Prasad, N., Yang, J., Chen, S.-C., Ayers, G. D., Pawlikowski, J. S., Raman, D., Sosman, J. A., Kelley, M., et al. (2016) · JNCI Journal of the National Cancer Institute

Cancer Immunotherapy and BiomarkersTelomeres, Telomerase, and Senescence

Cited by 95

A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Xia, J., Jia, P., Hutchinson, K. E., Dahlman, K. B., Johnson, D., Sosman, J., Pao, W., & Zhao, Z. (2014) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 94

Treatment of Advanced Renal Cell Carcinoma with the Combination Bevacizumab/Erlotinib/Imatinib: A Phase I/II Trial

Hainsworth, J. D., Spigel, D. R., Sosman, J. A., Burris, H. A., Farley, C., Cucullu, H., Yost, K., Hart, L. L., Sylvester, L., Waterhouse, D. M., et al. (2007) · Clinical Genitourinary Cancer

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 80

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 75

Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand

Patrinely, J. R., Young, A. C., Quach, H., Williams, G. R., Ye, F., Fan, R., Horn, L., Beckermann, K. E., Gillaspie, E. A., Sosman, J. A., et al. (2020) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersCancer survivorship and care

Cited by 61

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma

Giricz, O., Mo, Y., Dahlman, K. B., Cotto-Rios, X. M., Vardabasso, C., Nguyen, H., Matusow, B., Bartenstein, M., Polishchuk, V., Johnson, D. B., et al. (2018) · JCI Insight

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 40

Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy

Reinstein, Z. Z., Zhang, Y., Ospina, O. E., Nichols, M. D., Chu, V. A., Pulido, A. D. M., Prieto, K., Nguyen, J. V., Yin, R., Moran Segura, C., et al. (2024) · Cancer Discovery

Polyomavirus and related diseasesCancer Immunotherapy and Biomarkers

Cited by 33